use
novel data sets
biochemical data
T2D subtypes
diabetes prevention
diabetes mellitus
improved T2D taxonomy
discovery of novel biomarkers
adoption of novel strategies
precision medicine
large expertise
diabetes-relevant IMI1 projects
effective data federation
large European cohorts
molecular taxonomy of type
development of pharmaceutical activities
multi-omic maps of key T2D-relevant tissues
regulatory approval
health economics
patient segmentation
patient engagement
causal biomarkers
progression of prediabetes
comprehensive genetic analyses
clinical trial design
physiological experimental approaches
establishment of regulatory paths
systems biology approaches
stated goal of RHAPSODY
prominent European experts
organs
datasets
samples
leaders
disease modification
ability
access
treatment
risk
goals
plans